Business
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 monthsPRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, toda
About this update from Transcenta Holding Limited
[{"type":"text","content":"Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months","length":186,"tagName":"p"},{"type":"text","content":"PRINCETON, N.J. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer. The new findings were showcased in a poster presentation (Abstract #299P) at the ESMO Asia Congress 2025 in Singapore.","length":666,"tagName":"p"},{"type":"text","content":"This new analysis reinforces the encouraging clinical benefit of the osemitamab triple combination regimen in the ongoing study. In the 26 patients with CLDN18.2 expression ≥40%, ≥2+ and known PD-L1 CPS, the median PFS reached 16.6 months, with an ORR of 68% and a median DoR of 18 months at a 25.8-month median follow-up. Notably, better PFS outcomes were observed in patients with higher CLDN18.2 expression compared to lower CLDN18.2 expressors in both PD-L1 CPS<1 and ≥1 subgroups, which indicated the potential treatment benefit of osemitamab is consistent regardless of PD-L1 expression.","length":596,"tagName":"p"},{"type":"text","content":"The safety profile was similar to that previously presented at ASCO 2025.","length":73,"tagName":"p"},{"type":"text","content":"“The exploratory efficacy analysis continues to show promising clinical benefit with osemitamab when combined with standard-of-care therapy,” said Professor Lin Shen, Director, Department of Gastrointestinal Oncology and Phase I Clinical Trial Center at Peking University Cancer Hospital; and Principal Investigator of the trial. “The consistency of benefit across different PD-L1 subgroups is particularly noteworthy and suggests that this regimen may offer meaningful improvement for a broad population of patients with advanced G/GEJ cancer.”","length":545,"tagName":"p"},{"type":"text","content":"“We are encouraged to see...